In the ME, the stromal cells of the tumor and the immune infiltrate composition have an effect on DLBCL progression.14, 15, 16One of the recent trends in the treatment of DLBCL is blockade of an immune checkpoint that targets the programmed death of cell ligand 1 receptors (PD-L1).17These checkpoints are receptors found on the surface of immune cells such as B-lymphocytes, T lymphocytes, dendritic cells and macrophages, and are very important in playing essential roles in tumor progression.18 This evidence concerns the gene CD274 and neoplasm.